Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer: A Prospective, Exploratory, Open-Label Clinical Study
Latest Information Update: 27 May 2025
At a glance
- Drugs Fruquintinib (Primary) ; Gumarontinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 May 2025 New trial record